Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
Alec Paschalis,Alec Paschalis,Beshara Sheehan,Ruth Riisnaes,Daniel Nava Rodrigues,Bora Gurel,Claudia Bertan,Ana Ferreira,Maryou B. Lambros,George Seed,Wei Yuan,David Dolling,Jon Welti,Antje Neeb,Semini Sumanasuriya,Semini Sumanasuriya,Pasquale Rescigno,Diletta Bianchini,Diletta Bianchini,Nina Tunariu,Nina Tunariu,Suzanne Carreira,Adam Sharp,Adam Sharp,Wim J.G. Oyen,Johann S. de Bono,Johann S. de Bono +26 more
TLDR
It is reported that the presence of prostate-specific membrane antigen (PSMA) is extremely variable both within one patient and between different patients, and this may limit the usefulness of PSMA scans and PSMA-targeted therapies.About:
This article is published in European Urology.The article was published on 2019-10-01 and is currently open access. It has received 217 citations till now. The article focuses on the topics: Prostate cancer & Prostate.read more
Citations
More filters
Journal ArticleDOI
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor,Johann S. de Bono,Kim N. Chi,Karim Fizazi,Ken Herrmann,Kambiz Rahbar,Scott T. Tagawa,Luke T. Nordquist,Nitin Vaishampayan,Ghassan El-Haddad,Chandler H Park,Tomasz M. Beer,Alison Armour,Wendy J Pérez-Contreras,Michelle DeSilvio,Euloge Kpamegan,Germo Gericke,Richard A. Messmann,Michael J. Morris,Bernd J. Krause,Vision Investigators +20 more
TL;DR: In this paper, Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer and remains fatal despite recent advances in medical technology.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Alberto Bossi,Robert G. Bristow,Brett S. Carver,Daniel Castellano,Byung Ha Chung,Noel W. Clarke,Gedske Daugaard,Ian D. Davis,Johann S. de Bono,Rodolfo Borges dos Reis,Charles G. Drake,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Celestia S. Higano,Nicolas James,Philip W. Kantoff,Pirkko-Liisa Kellokumpu-Lehtinen,Raja B. Khauli,Gero Kramer,Chris Logothetis,Fernando C. Maluf,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Vedang Murthy,William Oh,Piet Ost,Anwar R. Padhani,Chris Parker,Colin C. Pritchard,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Oliver Sartor,Howard I. Scher,Avishay Sella,Neal D. Shore,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Ian F. Tannock,Bertrand Tombal,Riccardo Valdagni,Thomas Wiegel,Aurelius Omlin +60 more
TL;DR: The presented expert voting results can be used for support in areas of management of men with APC where there is no high-level evidence, but individualised treatment decisions should as always be based on all of the data available.
Journal ArticleDOI
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]
Silke Gillessen,Gerhardt Attard,Tomasz M. Beer,Himisha Beltran,Anders Bjartell,Alberto Bossi,Alberto Briganti,Robert G. Bristow,Kim N. Chi,Noel W. Clarke,Ian D. Davis,Johann S. de Bono,Charles G. Drake,Ignacio Duran,Ros Eeles,Eleni Efstathiou,Christopher P. Evans,Stefano Fanti,Felix Y. Feng,Karim Fizazi,Mark Frydenberg,Martin E. Gleave,Susan Halabi,Axel Heidenreich,Axel Heidenreich,Daniel Heinrich,Celestia S. Higano,Celestia S. Higano,Michael S Hofman,Michael S Hofman,Maha Hussain,Nicolas James,Ravindran Kanesvaran,Philip W. Kantoff,Philip W. Kantoff,Raja B. Khauli,Raya Leibowitz,Chris Logothetis,Chris Logothetis,Fernando C. Maluf,Robin Millman,Alicia K. Morgans,Michael J. Morris,Nicolas Mottet,Hind Mrabti,Declan G. Murphy,Declan G. Murphy,Vedang Murthy,William Oh,Piet Ost,Joe M. O'Sullivan,Joe M. O'Sullivan,Anwar R. Padhani,Chris Parker,Darren M.C. Poon,Colin C. Pritchard,Robert E. Reiter,Mack Roach,Mark A. Rubin,Charles J. Ryan,Fred Saad,Juan Pablo Sade,Oliver Sartor,Howard I. Scher,Howard I. Scher,Neal D. Shore,Eric J. Small,Matthew R. Smith,Howard R. Soule,Cora N. Sternberg,Thomas Steuber,Hiroyoshi Suzuki,Christopher Sweeney,Matthew R. Sydes,Mary-Ellen Taplin,Bertrand Tombal,Levent Türkeri,Inge M. van Oort,Almudena Zapatero,Aurelius Omlin,Aurelius Omlin +80 more
TL;DR: These voting results from a panel of prostate cancer experts can help clinicians and patients navigate controversial areas of advanced prostate management for which high-level evidence is sparse and provide a practical guide to help clinicians discuss therapeutic options with patients.
Journal ArticleDOI
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
John Violet,Shahneen Sandhu,Amir Iravani,Justin Ferdinandus,Sue-Ping Thang,Grace Kong,Aravind S. Ravi Kumar,Tim Akhurst,David A. Pattison,Alexis Beaulieu,Jennifer Mooi,Ben Tran,Christina Guo,Victor Kalff,Declan G. Murphy,Price Jackson,Peter Eu,Mark Scalzo,Scott Williams,Rodney J. Hicks,Michael S Hofman +20 more
TL;DR: This expanded 50-patient cohort of men with extensive prior therapy confirms an earlier report of high response rates, low toxicity, and improved quality of life with 177Lu-PSMA radioligand therapy.
Journal ArticleDOI
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Eric Powers,Georgia-Sofia Karachaliou,Georgia-Sofia Karachaliou,Chester Kao,Michael R. Harrison,Michael R. Harrison,Christopher J. Hoimes,Christopher J. Hoimes,Daniel J. George,Daniel J. George,Andrew J. Armstrong,Andrew J. Armstrong,Tian Zhang,Tian Zhang +13 more
TL;DR: The progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials are highlighted.
References
More filters
Journal ArticleDOI
Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
Cole Trapnell,Adam Roberts,Loyal A. Goff,Loyal A. Goff,Loyal A. Goff,Geo Pertea,Daehwan Kim,Daehwan Kim,David R. Kelley,David R. Kelley,Harold Pimentel,Steven L. Salzberg,John L. Rinn,John L. Rinn,Lior Pachter +14 more
TL;DR: This protocol begins with raw sequencing reads and produces a transcriptome assembly, lists of differentially expressed and regulated genes and transcripts, and publication-quality visualizations of analysis results, which takes less than 1 d of computer time for typical experiments and ∼1 h of hands-on time.
Journal ArticleDOI
Integrative clinical genomics of advanced prostate cancer
Dan R. Robinson,Eliezer M. Van Allen,Eliezer M. Van Allen,Yi-Mi Wu,Nikolaus Schultz,Robert J. Lonigro,Juan Miguel Mosquera,Bruce Montgomery,Mary-Ellen Taplin,Colin C. Pritchard,Gerhardt Attard,Gerhardt Attard,Himisha Beltran,Wassim Abida,Robert K. Bradley,Jake Vinson,Xuhong Cao,Pankaj Vats,Lakshmi P. Kunju,Maha Hussain,Felix Y. Feng,Scott A. Tomlins,Kathleen A. Cooney,David Smith,Christine Brennan,Javed Siddiqui,Rohit Mehra,Yu Chen,Yu Chen,Dana E. Rathkopf,Dana E. Rathkopf,Michael J. Morris,Michael J. Morris,Stephen B. Solomon,Jeremy C. Durack,Victor E. Reuter,Anuradha Gopalan,Jianjiong Gao,Massimo Loda,Rosina T. Lis,Michaela Bowden,Michaela Bowden,Stephen P. Balk,Glenn C. Gaviola,Carrie Sougnez,Manaswi Gupta,Evan Y. Yu,Elahe A. Mostaghel,Heather H. Cheng,Hyojeong Mulcahy,Lawrence D. True,Stephen R. Plymate,Heidi Dvinge,Roberta Ferraldeschi,Roberta Ferraldeschi,Penny Flohr,Penny Flohr,Susana Miranda,Susana Miranda,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Nina Tunariu,Nina Tunariu,Joaquin Mateo,Joaquin Mateo,Raquel Perez-Lopez,Raquel Perez-Lopez,Francesca Demichelis,Francesca Demichelis,Brian D. Robinson,Marc H. Schiffman,David M. Nanus,Scott T. Tagawa,Alexandros Sigaras,Kenneth Eng,Olivier Elemento,Andrea Sboner,Elisabeth I. Heath,Howard I. Scher,Howard I. Scher,Kenneth J. Pienta,Philip W. Kantoff,Johann S. de Bono,Johann S. de Bono,Mark A. Rubin,Peter S. Nelson,Levi A. Garraway,Levi A. Garraway,Charles L. Sawyers,Arul M. Chinnaiyan +89 more
TL;DR: This cohort study provides clinically actionable information that could impact treatment decisions for affected individuals and identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF.
Journal ArticleDOI
The causes and consequences of genetic heterogeneity in cancer evolution.
TL;DR: Insight is gained into the common pathways of tumour evolution that could support the development of future therapeutic strategies and shape the evolution of the cancer genome through a plethora of mechanisms.
Journal ArticleDOI
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo,Suzanne Carreira,Shahneen Sandhu,Susana Miranda,Helen Mossop,Raquel Perez-Lopez,Daniel Nava Rodrigues,Dan R. Robinson,Aurelius Omlin,Nina Tunariu,Gunther Boysen,Nuria Porta,Penny Flohr,Alexa Gillman,Ines Figueiredo,Claire Paulding,George Seed,Suneil Jain,Christy Ralph,Andrew Protheroe,Syed A. Hussain,Robert Jones,Tony Elliott,Ursula McGovern,Diletta Bianchini,Jane C. Goodall,Zafeiris Zafeiriou,Chris T. Williamson,Roberta Ferraldeschi,Ruth Riisnaes,Bernardette Ebbs,Gemma Fowler,Desamparados Roda,Wei Yuan,Yi-Mi Wu,Xuhong Cao,Rachel Brough,Helen Pemberton,Roger A'Hern,Amanda Swain,Lakshmi P. Kunju,Rosalind A. Eeles,Gerhardt Attard,Christopher J. Lord,Alan Ashworth,Mark A. Rubin,Karen E. Knudsen,Felix Y. Feng,Arul M. Chinnaiyan,Emma Hall,Johann S. de Bono +50 more
TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
Journal Article
Prostate-specific membrane antigen expression in normal and malignant human tissues.
TL;DR: The decrease in PSMA immunoreactivity noted in advanced prostate cancer suggests that expression of this molecule may be linked to the degree of tumor differentiation and the neoexpression of PSMA in endothelial cells of capillary beds in certain tumors may be related to tumor angiogenesis and suggests a potential mechanism for specific targeting of tumor neovasculature.
Related Papers (5)
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Michael S Hofman,Michael S Hofman,John Violet,Rodney J. Hicks,Rodney J. Hicks,Justin Ferdinandus,Sue Ping Thang,Tim Akhurst,Tim Akhurst,Amir Iravani,Grace Kong,Aravind S. Ravi Kumar,Declan G. Murphy,Declan G. Murphy,Peter Eu,Price Jackson,Mark Scalzo,Scott Williams,Shahneen Sandhu,Shahneen Sandhu +19 more
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Kambiz Rahbar,Hojjat Ahmadzadehfar,Clemens Kratochwil,Uwe Haberkorn,Michael Schäfers,Markus Essler,Richard P. Baum,Harshad R. Kulkarni,Matthias Schmidt,Alexander Drzezga,Peter Bartenstein,Andreas Pfestroff,Markus Luster,Ulf Lützen,Marlies Marx,Vikas Prasad,Winfried Brenner,Alexander Heinzel,Felix M. Mottaghy,Juri Ruf,Philipp T. Meyer,Martin Heuschkel,Maria Eveslage,Martin Bögemann,Wolfgang P. Fendler,Bernd J. Krause +25 more
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S Hofman,Michael S Hofman,Nathan Lawrentschuk,Roslyn J. Francis,Roslyn J. Francis,Colin Tang,Ian Vela,Paul Thomas,Paul Thomas,Natalie Rutherford,Jarad Martin,Mark Frydenberg,Ramdave Shakher,Lih-Ming Wong,Kim Taubman,Sze Ting Lee,Edward Hsiao,Paul Roach,Michelle K. Nottage,Ian Kirkwood,Ian Kirkwood,Dickon Hayne,Emma Link,Emma Link,Petra Marusic,Anetta Matera,Alan Herschtal,Amir Iravani,Amir Iravani,Rodney J. Hicks,Rodney J. Hicks,Scott Williams,Scott Williams,Declan G. Murphy,Declan G. Murphy +34 more
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
George L. Wright,George L. Wright,B. Mayer Grob,B. Mayer Grob,Cara Haley,Cara Haley,Katie Grossman,Katie Grossman,Kathy Newhall,Kathy Newhall,Daniel P. Petrylak,Daniel P. Petrylak,John Troyer,John Troyer,Alice Konchuba,Alice Konchuba,Paul F. Schellhammer,Paul F. Schellhammer,Richard Moriarty,Richard Moriarty +19 more